Clinical trials: Vitiligo Vulgaris
Vitiligo, Generalized
Vitiligo Treatment by Targeting TYK2 Mediated Responses
Vitiligo affects approximately 1 to 2% of the global population and significantly impacts people's quality of life. Achieving the best treatment outcomes for vitiligo involves addressing the autoimmune inflammatory response to…
- Trial name
- ViTYK (NCT06327321)
- Testing
- Deucravacitinib, Volunteer without treatment
- Where
- 5 sites in France
- Volunteers
- 128 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Vitiligo - Macular Depigmentation
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation.
- Trial name
- NCT07016113
- Testing
- 0.005% latanoprost gel, 0.1% mometasone furoate cream
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Universitas Padjadjaran
Vitiligo, CD25 Deficiency
Tregs CD25 CXCL9 in Vitiligo
Clinical significance of circulating T regulatory cells , soluble CD25 and CXCL9 to assess disease activity of vitiligo.
- Conditions
- Vitiligo, CD25 Deficiency, Chemokine (C-X-C Motif), Tregs
- Trial name
- NCT05569096
- Testing
- ELIZA , Flowcytometry
- Volunteers
- 40 people
- Sponsor
- Assiut University
Vitiligo
A Comparative Study on the Efficacy of Blue Light Emitting Diodes Therapy Versus Targeted Narrow Band UVB in Stable Non-segmental Vitiligo Patients.
A comparative study on the efficacy of blue light emitting diodes therapy versus targeted Narrow band UVB in stable non-segmental vitiligo patients.
- Trial name
- Nb-UVB (NCT07174024)
- Testing
- Narrow Band UVB Treatment, blue light emitting diode
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Vitiligo
Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo
Vitiligo is a depigmenting skin disease common. Vitiligo is caused by the disappearance of melanocytes in the epidermis. Vitiligo is the cause of disfigurement, psychological and social, that sounds a lot about the quality of…
- Trial name
- Viticell (NCT01511965)
- Testing
- autologous (cellular therapy)
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
VITILIGO
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
This study aims to evaluate some differences in the immune system between patients with vitiligo and patients without the disease.
- Trial name
- NCT03249064
- Testing
- CD 91 levels, Tregs
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Vitiligo
Exosomal Markers CD63 and CD9 in Vitiligo Before and After NB-UVB Therapy
This study evaluated the expression of the exosomal markers CD63 and CD9 in the skin of patients with vitiligo and assessed changes in their expression after narrow-band ultraviolet B (NB-UVB) therapy.
- Trial name
- NCT07796893
- Testing
- Narrow-Band Ultraviolet B (NB-UVB) Therapy
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Amany El-Agamy Ibrahim El-Samadony
Vitiligo
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
- Trial name
- NCT03468855
- Testing
- ATI-50002 topical solution
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aclaris Therapeutics, Inc.
Vitiligo
Evaluation of Pyroptosis-related Indicators in the Pathogenesis of Vitiligo:Across-sectional Comparative Study
Vitiligo is an acquired pigmentary disorder on skin and/or mucosae, which is characterized by death of melanocytes (MCs), affecting 0.5%-2% of the population worldwide (1).
- Trial name
- NCT06261086
- Testing
- evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sohag University
Vitiligo
Evaluation of the Efficacy and the Cutaneous Acceptability of a Dermocosmetic Product in the Repigmentation of Vitiligo
Study in proof of concept; Double blind study; Comparative study, versus placebo in intra-individual Three parallel groups testing different dosages / combinations of treatments Randomized.
- Trial name
- NCT04171427
- Testing
- Lithium liposome
- Where
- Tunisia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Laboratoire Dermatologique ACM
Vitiligo
Effect of Procedural Variables on Outcome of Surgical Treatment of Vitiligo
ORSHFS grafts yielded lower cell counts than NCECS but the M-K ratio and resultant repigmentation did not show significant difference with better healing of the donor site.
- Trial name
- NCT02510651
- Testing
- Melanocyte-keratinocyte suspension
- Volunteers
- 40 people
- Sponsor
- Cairo University
Gingival Pigmentation
Influence of Adjunctive Acids Use on Esthetic Outcomes of Gingival Melanin Depigmentation: A Periodontal-Operative Pilot Randomized Clinical Trial
This pilot randomized clinical trial aims to evaluate the effect of adjunctive acid application on the esthetic outcomes of gingival melanin depigmentation.
- Trial name
- GMDAcidRCT (NCT07708792)
- Testing
- Citric acid
- Volunteers
- 30 people
- Sponsor
- Dijlah University
Vitiligo Vulgaris
Questionnaire and Laboratory Data on Vitiligo Vulgaris
Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals).
- Trial name
- NCT01206374
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- St. Luke's-Roosevelt Hospital Center
NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable…
- Trial name
- MTII-VIT (NCT07437560)
- Testing
- Melanotan II (MT-II), Narrowband UV-B (NB-UVB) phototherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hudson Biotech
Vitiligo
Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial
this randomized controlled trial aims to compare the effectiveness and safety of ruxolitinib monotherapy versus its combination with topical tacrolimus or topical corticosteroids in patients with non-segmental vitiligo involving…
- Trial name
- NCT07368673
- Testing
- ruxolitinib cream
- Where
- Pakistan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Dow University of Health Sciences
Vitiligo Vulgaris
Autologous Nanofat Injection for Treatment of Stable Vitiligo
This randomized, split-site, within-participant controlled clinical study evaluated the efficacy and safety of a single session of autologous nanofat injection as an adjunct to narrowband ultraviolet B (NB-UVB) phototherapy in 20…
- Trial name
- NCT07763262
- Testing
- Autologous Nanofat Injection, NB-UVB Phototherapy
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Benha University
Vitiligo
Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo
20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib
- Trial name
- NB-UVB (NCT07044141)
- Testing
- Azathioprine, Tofacitinib
- Where
- Pakistan
- Volunteers
- 20 people
- Sponsor
- Lahore General Hospital
Atopic Dermatitis, Psoriasis
Determinants of Chronic Inflammatory Skin Disease Trajectories
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation…
- Conditions
- Atopic Dermatitis, Psoriasis, Lichen Planus, Alopecia Areata
- Trial name
- NCT05928169
- Testing
- Topical and systemic drugs
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Vitiligo
Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.
This study aims to compare the efficacy of topical 5-fluorouracil versus topical latanoprost after skin microneedling in the induction of skin repigmentation in localized stable vitiligo patients.
- Trial name
- NCT05513924
- Testing
- Latanoprost 0.005% Ophthalmic Solution, 5Fluorouracil
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- South Valley University
Vitiligo
Role of NGAL in Vitiligo
Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo
- Trial name
- NCT05290077
- Testing
- NGAL
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sohag University